Monotherapy with either fibrates or statins suggested a significantly greater effect of fibrates in lowering plasma Fib concentrations .
According to these findings , mechanisms associated with fibrinogen metabolism might be responsible for the distinct effects of statins and fibrates in reducing cardiovascular endpoints
BACKGROUND Several studies suggest differences between fibrates and statins in lowering plasma fibrinogen ( Fib ) concentrations , but the evidence is not definitive .
Therefore , the aim of this meta- analysis of head-to-head r and omized trials was to compare the efficacy of statins and fibrates on plasma Fib concentrations .
Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis.
BACKGROUND HMG-CoA reductase inhibitors ( statins ) reduce the risk of venous thromboembolism ( VTE ) in healthy people .  Statins reduce levels of inflammation biomarkers ; however , the mechanism for the reduction in VTE risk is unknown . AIM In a large cohort of healthy people , we studied associations of statin use with plasma hemostatic factors related to VTE risk . METHODS Cross-sectional analyses were performed in the Multi-Ethnic Study of Atherosclerosis ( MESA ) , a cohort study of 6814 healthy men and women aged 45 - 84 years , free of clinical cardiovascular disease at baseline ; 1001 were using statins at baseline . Twenty-three warfarin users were excluded . Age , race and sex-adjusted mean hemostatic factor levels were compared between statin users and non-users , and multivariable linear regression models were used to assess associations of statin use with hemostatic factors , adjusted for age , race/ethnicity , education , income , aspirin use , hormone replacement therapy ( in women ) , and major cardiovascular risk factors . RESULTS Participants using statins  had lower adjusted levels of D-dimer ( - 9 % ) , C-reactive protein ( - 21 % ) and factor VIII ( - 3 % ) than non-users ( P < 0.05 ) . Homocysteine and von Willebr and factor levels were non-significantly lower with statin use . Higher fibrinogen ( 2 % ) and plasminogen activator inhibitor-1 ( 22 % ) levels were observed among statin users than among non-users ( P < 0.05 ) . Further adjustment for LDL and triglyceride levels did not attenuate the observed differences in these factors with statin use . CONCLUSIONS Findings of lower D-dimer , FVIII and C-reactive protein levels with statin use suggest hypotheses for mechanisms whereby statins might lower VTE risk . A prospect i ve study or clinical trial linking these biochemical differences to VTE outcomes in  statin users and non-users is warranted
Monotherapy with either fibrates or statins suggested a significantly greater effect of fibrates in lowering plasma Fib concentrations .
According to these findings , mechanisms associated with fibrinogen metabolism might be responsible for the distinct effects of statins and fibrates in reducing cardiovascular endpoints
BACKGROUND Several studies suggest differences between fibrates and statins in lowering plasma fibrinogen ( Fib ) concentrations , but the evidence is not definitive .
Therefore , the aim of this meta- analysis of head-to-head r and omized trials was to compare the efficacy of statins and fibrates on plasma Fib concentrations .